X hits on this document

PDF document

Wan-Wan Lin1 and Michael Karin2 - page 8 / 9





8 / 9

review series

  • 35.

    Troost, E., et al. 2003. The role of interleukin- 1beta and other potential genetic markers as indi- cators of gastric cancer risk. Can. J. Gastroenterol. 17(Suppl. B):8B–12B.

  • 36.

    Apte, R.N., et al. 2006. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25:387–408.

  • 37.

    Lewis, A.M., Varghese, S., Xu, H., and Alexander,

    • H.

      R. 2006. Interleukin–1 and cancer progression: the emerging role of interleukin–1 receptor antago- nist as a novel therapeutic agent in cancer treatment.

    • J.

      Transl. Med. 4:48.

  • 38.

    Harmey, J.H., et al. 2002. Lipopolysaccharide- induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer. 101:415–422.

  • 39.

    Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., and Karin,

    • M.

      2004. Inhibition of NF-kB in cancer cells con- verts inflammation-induced tumor growth mediat- ed by TNF-α to TRAIL-mediated tumor regression. Cancer Cell. 6:297–305.

  • 40.

    Almasan, A., and Ashkenazi, A. 2003. Apo2L/ TRAIL: apoptosis signaling, biology, and poten- tial for cancer therapy. Cytokine Growth Factor Rev. 14:337–348.

  • 41.

    Jego, G., et al. 2006. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 20:1130–1137.

  • 42.

    Bohnhorst, J., et al. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 20:1138–1144.

  • 43.

    Lin, W.J., and Yeh, W.C. 2005. Implication of Toll- like receptor and tumor necrosis factor alpha sig- naling in septic shock. Shock. 24:206–209.

  • 44.

    Mocellin, S., Rossi, C.R., Pilati, P., and Nitti, D.

      • 2005.

        Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 16:35–53.

  • 45.

    Yang, H., et al. 2006. TNF-α inhibits asbestos- induced cytotoxicity via a NF-kB–dependent pathway, a possible mechanism for asbestos- induced oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 103:10397–10402.

  • 46.

    Elgert, K.D., Alleva, D.G., and Mullins, D. W. 1998. Tumor-induced immune dysfunction: the macro- phage connection. J. Leukoc. Biol. 64:275–290.

  • 47.

    Moore, R.J., et al. 1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcino- genesis. Nat. Med. 5:828–831.

  • 48.

    Arnott, C.H., et al. 2004. Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene. 23:1902–1910.

  • 49.

    Pikarsky, E., et al. 2004. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466.

  • 50.

    Knight, B., et al. 2000. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice.

    • J.

      Exp. Med. 192:1809–1818.

  • 51.

    Kitakata, H., et al. 2002. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 62:6682–6687.

  • 52.

    LeBlanc, H.N., and Ashkenazi, A. 2003. Apo2L/ TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75.

  • 53.

    Takeda, K., et al. 2002. Critical role for tumor necro- sis factor–related apoptosis-inducing ligand in immune surveillance against tumor development.

    • J.

      Exp. Med. 195:161–169.

  • 54.

    Schmaltz, C., et al. 2002. T cells require TRAIL for optimal graft-versus tumor activity. Nat. Med. 8:1433–1437.

  • 55.

    Ishihara, K., and Hirano, T. 2002. IL-6 in autoim- mune disease and chronic inflammatory prolifera- tive disease. Cytokine Growth Factor Rev. 13:357–368.

  • 56.

    Hodge, D.R., Hurt, E.M., and Farrar, W.L. 2005.

The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer. 41:2502–2512.

  • 57.

    O’Shea, J.J., Gadina, M., and Schreiber, R.D. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 109(Suppl.):S121–S131.

  • 58.

    Haura, E.B., Turkson, J., and Jove, R. 2005. Mecha- nisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2:315–324.

  • 59.

    Osborne, J., Moore, P.S., and Chang, Y. 1999. KSHV- encoded viral IL-6 activates multiple human IL-6 signalling pathways. Hum. Immunol. 60:921–927.

  • 60.

    Bommert, K., Bargou, R.C., and Stuhmer, T. 2006. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer. 42:1574–1580.

  • 61.

    Cozen, W., et al. 2004. IL-6 levels and genotype are asso- ciated with risk of young adult Hodgkin lymphoma. Blood. 103:3216–3221.

  • 62.

    Berger, F.G. 2004. The interleukin-6 gene: a sus- ceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res. Treat. 88:281–285.

  • 63.

    Gado, K., et al. 2001. Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica. 86:227–236.

  • 64.

    Chauhan, D., et al. 1996. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood. 87:1104–1112.

  • 65.

    Feng, J., et al. 2006. The rational designed antago- nist derived from the complex structure of interleu- kin-6 and its receptor affectively blocking interleu- kin-6 might be a promising treatment in multiple myeloma. Biochimie. 88:1265–1273.

  • 66.

    Becker, C., et al. 2004. TGFβ suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 21:491–501.

  • 67.

    Greten, F.R., et al. 2004. IKKβ links inflammation and tumorigenesis in a mouse model of colitis- associated cancer. Cell. 118:285–296.

  • 68.

    Rose-John, S., Scheller, J., Elson, G., and Jones, S.A.

    • 2006.

      Interleukin-6 biology is coordinated by mem- brane-bound and soluble receptors: role in inflam- mation and cancer. J. Leukoc. Biol. 80:227–236.

  • 69.

    Abroun, S., et al. 2004. Receptor synergy of inter- leukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α. Blood. 103:2291–2298.

  • 70.

    Mangan, P.R., et al. 2006. Transforming growth factor-β induces development of the TH17 lineage. Nature. 441:231–234.

  • 71.

    Cho, M.L., et al. 2006. STAT3 and NF-kB signal pathway is required for IL-23–mediated IL-17 pro- duction in spontaneous arthritis animal model IL-1 receptor antagonist–deficient mice. J. Immunol. 176:5652–5661.

  • 72.

    Moseley, T.A., Haudenschild, D.R., Rose, L., and Reddi, A.H. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14:155–174.

  • 73.

    Witowski, J., Ksiazek, K., and Jorres, A. 2004. Inter- leukin-17: a mediator of inflammatory responses. Cell Mol. Life Sci. 61:567–579.

  • 74.

    Langrish, C.L., et al. 2005. IL-23 drives a patho- genic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233–240.

  • 75.

    Park, H., et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133–1141.

  • 76.

    Ruddy, M.J., et al. 2004. Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer-binding protein family members. J. Biol. Chem. 279:2559–2567.

  • 77.

    Tartour, E., et al. 1999. Interleukin 17, a T-cell– derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59:3698–3704.

  • 78.

    Numasaki, M., et al. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human

non-small cell lung cancer in SCID mice through promoting CXCR-2–dependent angiogenesis.

      • J.

        Immunol. 175:6177–6189.

  • 79.

    Numasaki, M., et al. 2003. Interleukin-17 pro- motes angiogenesis and tumor growth. Blood. 101:2620–2727.

  • 80.

    Benchetrit, F., et al. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism. Blood. 99:2114–2121.

  • 81.

    Watford, W.T., et al. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202:139–156.

  • 82.

    Trinchieri, G. 2003. Interleukin-12 and the regula- tion of innate resistance and adaptive immunity. Nat. Rev. 3:133–146.

  • 83.

    Hao, J.S., and Shan, B.E. 2006. Immune enhance- ment and anti-tumour activity of IL-23. Cancer Immunol. Immunother. 55:1426–1431.

  • 84.

    Murphy, C.A., et al. 2003. Divergent pro- and antiin- flammatory roles for IL-23 and IL-12 in joint auto- immune inflammation. J. Exp. Med. 198:1951–1957.

  • 85.

    Langowski, J.L., et al. 2006. IL-23 promotes tumour incidence and growth. Nature. 442:461–465.

  • 86.

    Ugai, S., et al. 2003. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell–dependent and

    • independent antitumor effects. Cancer Gene Ther. 10:771–778.

  • 87.

    Lo, C.H., et al. 2003. Antitumour and antimeta- static activity of IL-23. J. Immunol. 171:600–607.

  • 88.

    Pestka, S., et al. 2004. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22:929–979.

  • 89.

    Schottelius, A.J., Mayo, M.W., Sartor, R.B., and Baldwin, A.S., Jr. 1999. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem. 274:31868–31874.

  • 90.

    Hoentjen, F., Sartor, R.B., Ozaki, M., and Jobin,

      • C.

        2005. STAT3 regulates NF-kB recruitment to the IL-12p40 promoter in dendritic cells. Blood. 105:689–696.

  • 91.

    Moore, K.W., et al. 2001. Interleukin-10 and the inter- leukin-10 receptor. Annu. Rev. Immunol. 19:683–765.

  • 92.

    Berg, D.J., et al. 1996. Enterocolitis and colon can- cer in interleukin-10–deficient mice are associated with aberrant cytokine production and CD4+ TH1- like responses. J. Clin. Invest. 98:1010–1020.

  • 93.

    Sellon, R.K., et al. 1998. Resident enteric bacteria are necessary for development of spontaneous coli- tis and immune system activation in interleukin- 10–deficient mice. Infect. Immun. 66:5224–5231.

  • 94.

    Erdman, S.E., et al. 2003. CD4+CD25+ regula- tory T lymphocytes inhibit microbially-induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162:691–702.

  • 95.

    Maloy, K., et al. 2003. CD4+CD25+ Tr cells sup- press innate immune pathology through cytokine- dependent mechanisms. J. Exp. Med. 197:111–119.

  • 96.

    Erdman, S.E., et al. 2003. CD4+CD25+ regulatory lym- phocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 63:6042–6050.

  • 97.

    Erdman, S.E., et al. 2005. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 65:3998–4004.

  • 98.

    Segal, B.M., Glass, D.D., and Shevach, E.M. 2002. Cutting edge: IL-10–producing CD4+ T cells mediate tumor rejection. J. Immunol. 168:1–4.

  • 99.

    Huang, S., Ullrich, S.E., and Bar-Eli, M. 1999. Reg- ulation of tumor growth and metastasis by inter- leukin-10: the melanoma experience. J. Interferon Cytokine Res. 19:697–703.

  • 100.

    Kohno, T., et al. 2003. Interleukin-10–mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res. 63:5091–5094.

  • 101.

    Leach, M.W., and Rennick, D.M. 1998. IL-12, but not IFNgamma, plays a major role in sustaining


The Journal of Clinical Investigation


Volume 117

Number 5

May 2007

Document info
Document views35
Page views35
Page last viewedMon Dec 19 11:27:06 UTC 2016